Skip to main
GRDN

GRDN Stock Forecast & Price Target

GRDN Analyst Ratings

Based on 3 analyst ratings
Buy
Strong Buy 33%
Buy 67%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Guardian Pharmacy Services Inc. demonstrates a strong financial outlook due to its differentiated technology-enabled services that improve medication adherence and reduce care costs for residents in long-term care facilities. The company's robust tech capabilities are anticipated to enhance efficiency and margin through the integration of these platforms into newly acquired operations, positioning Guardian well within the value-based care landscape. Additionally, the utilization of robotic dispensing technology has significantly boosted operational efficiency, reducing the time to fulfill requests to less than one day, and further strengthens their competitive advantage and market share in the pharmacy services sector.

Bears say

The financial outlook for Guardian Pharmacy Services Inc. appears negative due to several significant operational risks, including potential regulatory and reimbursement changes that could impact profitability. Additionally, challenges related to relationship management with long-term care facilities (LTCFs) and ongoing difficulties in hiring and retaining clinical staff may hinder the company's ability to maintain service quality. Furthermore, the reliance on technology assets and the threat of supply chain disruptions could further complicate operations, potentially undermining revenue generation and overall performance.

GRDN has been analyzed by 3 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 67% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Guardian Pharmacy Services Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Guardian Pharmacy Services Inc (GRDN) Forecast

Analysts have given GRDN a Buy based on their latest research and market trends.

According to 3 analysts, GRDN has a Buy consensus rating as of Feb 19, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $33.33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $33.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Guardian Pharmacy Services Inc (GRDN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.